JP2025505198A5 - - Google Patents

Info

Publication number
JP2025505198A5
JP2025505198A5 JP2024546402A JP2024546402A JP2025505198A5 JP 2025505198 A5 JP2025505198 A5 JP 2025505198A5 JP 2024546402 A JP2024546402 A JP 2024546402A JP 2024546402 A JP2024546402 A JP 2024546402A JP 2025505198 A5 JP2025505198 A5 JP 2025505198A5
Authority
JP
Japan
Prior art keywords
methyl
alkyl
methylbenzo
oxetan
dioxol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024546402A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025505198A (ja
Filing date
Publication date
Priority claimed from PCT/IB2022/053367 external-priority patent/WO2022219495A1/en
Application filed filed Critical
Priority claimed from PCT/IB2023/051207 external-priority patent/WO2023152698A1/en
Publication of JP2025505198A publication Critical patent/JP2025505198A/ja
Publication of JP2025505198A5 publication Critical patent/JP2025505198A5/ja
Pending legal-status Critical Current

Links

JP2024546402A 2022-02-10 2023-02-10 肥満の治療のためのｇｌｐ１受容体の活性化因子としての２－（（４－（（ｓ）－２－（４－クロロ－２－フルオロフェニル）－２－メチルベンゾ［ｄ］［１，３］ジオキソール－４－イル）ピペリジン－１－イル）メチル）－１－（（（ｓ）－オキセタン－２－イル）メチル）－１ｈ－イミダゾール誘導体 Pending JP2025505198A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202263308843P 2022-02-10 2022-02-10
US63/308,843 2022-02-10
US202263323401P 2022-03-24 2022-03-24
US63/323,401 2022-03-24
PCT/IB2022/053367 WO2022219495A1 (en) 2021-04-12 2022-04-11 2-((4-((s)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-imidazole derivatives as activators of the glp1 receptor for the treatment of obesity
IBPCT/IB2022/053367 2022-04-11
US202263378749P 2022-10-07 2022-10-07
US63/378,749 2022-10-07
PCT/IB2023/051207 WO2023152698A1 (en) 2022-02-10 2023-02-10 2-((4-((s)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-imidazole derivatives as activators of the glp1 receptor for the treatment of obesity

Publications (2)

Publication Number Publication Date
JP2025505198A JP2025505198A (ja) 2025-02-21
JP2025505198A5 true JP2025505198A5 (enExample) 2025-03-03

Family

ID=85278359

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024546402A Pending JP2025505198A (ja) 2022-02-10 2023-02-10 肥満の治療のためのｇｌｐ１受容体の活性化因子としての２－（（４－（（ｓ）－２－（４－クロロ－２－フルオロフェニル）－２－メチルベンゾ［ｄ］［１，３］ジオキソール－４－イル）ピペリジン－１－イル）メチル）－１－（（（ｓ）－オキセタン－２－イル）メチル）－１ｈ－イミダゾール誘導体

Country Status (4)

Country Link
EP (1) EP4476212A1 (enExample)
JP (1) JP2025505198A (enExample)
TW (1) TW202342014A (enExample)
WO (1) WO2023152698A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT4408840T (pt) 2021-09-27 2025-10-07 Terns Pharmaceuticals Inc Ácidos benzimidazolocarboxílicos como agonistas de glp-1r
CN118401519A (zh) 2021-10-25 2024-07-26 拓臻制药公司 作为glp-1r激动剂的化合物
CN119095843A (zh) 2022-02-23 2024-12-06 拓臻制药公司 作为glp-1r激动剂的化合物
EP4568664B1 (en) 2023-04-07 2026-04-01 Terns Pharmaceuticals, Inc. Combination comprising a thr-beta agonist and a glp-1r agonist for use in treating obesity
CN120981457A (zh) 2023-09-14 2025-11-18 歌礼制药(中国)有限公司 Glp-1r激动剂及其治疗方法
TW202521534A (zh) 2023-11-24 2025-06-01 香港商歌禮製藥(中國)有限公司 Glp-1r 激動劑及其治療方法
WO2025158275A1 (en) 2024-01-24 2025-07-31 Pfizer Inc. Combination therapy using glucose-dependent insulinotropic polypeptide receptor antagonist compounds and glp-1 receptor agonist compounds
TW202600132A (zh) 2024-03-08 2026-01-01 美商安尼波那生物公司 用於治療肥胖症及提高減重之方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200303742A (en) 2001-11-21 2003-09-16 Novartis Ag Organic compounds
CA2525764C (en) 2003-05-20 2012-07-17 Novartis Ag N-acyl nitrogen heterocycles as ligands of peroxisome proliferator-activated receptors
EP2694092B1 (en) 2011-04-08 2017-01-04 Amgen Inc. Method of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15)
EP3683228A3 (en) 2012-01-26 2020-07-29 Amgen Inc. Growth differentiation factor 15 (gdf-15) polypeptides
CA2862516C (en) 2012-03-27 2023-02-14 Ngm Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
US9161966B2 (en) 2013-01-30 2015-10-20 Ngm Biopharmaceuticals, Inc. GDF15 mutein polypeptides
KR101993714B1 (ko) 2013-01-30 2019-06-28 엔지엠 바이오파마슈티컬스, 아이엔씨. 대사 장애를 치료하는데 이용하기 위한 조성물과 방법
US9862752B2 (en) 2013-07-31 2018-01-09 Amgen Inc. Growth differentiation factor 15 (GDF-15) constructs
EP3157947A1 (en) 2014-06-23 2017-04-26 Novartis AG Hsa-gdf-15 fusion polypeptide and use thereof
US10588980B2 (en) 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
RU2017101436A (ru) 2014-06-24 2018-07-24 Ново Нордиск А/С Mic-1 слитные белки и их применение
JP6946304B2 (ja) 2015-12-22 2021-10-06 ノバルティス アーゲー 増殖分化因子１５（ｇｄｆ−１５）を使用して代謝障害を処置するまたは軽快させる方法
US10934279B2 (en) * 2018-06-13 2021-03-02 Pfizer Inc. GLP-1 receptor agonists and uses thereof
WO2020234726A1 (en) * 2019-05-20 2020-11-26 Pfizer Inc. Combinations comprising benzodioxol as glp-1r agonists for use in the treatment of nash/nafld and related diseases
JP2023537501A (ja) * 2020-08-06 2023-09-01 ガシャーブラム・バイオ・インコーポレイテッド ヘテロ環ｇｌｐ－１アゴニスト

Similar Documents

Publication Publication Date Title
JP2025505198A5 (enExample)
RU2361860C2 (ru) Новые замещенные 3-сера-индолы
JP5201740B2 (ja) ヒトプロテインチロシンホスファターゼ阻害剤および使用法
RU2015136770A (ru) Хинолинамиды и хиназолинамиды в качестве модуляторов натриевых каналов
JP2019531320A5 (enExample)
TW200906306A (en) Isoxazoline compounds and their use in pest control
RU2004122407A (ru) Амидные производные в качестве активаторов gk
RU2008108984A (ru) Терапевтический агент от диабета
JP6925367B2 (ja) Ｐｐａｒアゴニスト、化合物、医薬組成物、及びその使用方法
RU2003134150A (ru) Замещенные карбоновыми кислотами оксазоловые производные в качестве ppar-альфа и гамма-активаторов при лечении диабета
JP2010516702A5 (enExample)
JP2006503081A5 (enExample)
RU2010134411A (ru) Фенилацетамидное производное
WO2005025567A1 (en) Benzothiazole derivatives for the treatment of diabetes
JP2016534124A5 (enExample)
BR112018006866B1 (pt) Compostos agonistas de ppar, composições farmacêuticas e métodos de uso dos mesmos
JP2005514432A5 (enExample)
JP2011500679A5 (enExample)
JP2006507247A5 (enExample)
WO2019088005A1 (ja) 爪白癬治療用の外用製剤
JP2019131544A5 (enExample)
JP2009501776A5 (enExample)
JP2025512098A5 (enExample)
JP2021523206A5 (enExample)
JP2010504321A5 (enExample)